HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
|
HER-2 overexpression
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
Trazimera (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
Ogivri (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
Herzuma (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
|
HER-2 overexpression
HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
Hormone Receptor Negative Breast Cancer
|
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
trastuzumab/hyaluronidase-oysk
|
HER-2 overexpression
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
Trazimera (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
Herzuma (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
Ogivri (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
Zercepac (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
Zercepac (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Esophageal Adenocarcinoma
Esophageal Adenocarcinoma
|
trastuzumab
Sensitive: A2 - Guideline
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Adenocarcinoma
Gastric Adenocarcinoma
|
trastuzumab
Sensitive: A2 - Guideline
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
|
HER-2 overexpression
HER-2 overexpression
|
Esophageal Adenocarcinoma
Esophageal Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Adenocarcinoma
Gastric Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
lapatinib
Sensitive: B - Late Trials
|
HER-2 overexpression
HER-2 overexpression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
trastuzumab + lapatinib
Sensitive: B - Late Trials
|
HER-2 overexpression
HER-2 overexpression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
lapatinib
Sensitive: B - Late Trials
|
HER-2 overexpression
HER-2 overexpression
|
Gallbladder Cancer
Gallbladder Cancer
|
trastuzumab
Sensitive: C1 - Off-label
|
HER-2 overexpression
HER-2 overexpression
|
Endometrial Adenocarcinoma
Endometrial Adenocarcinoma
|
trastuzumab
Sensitive: C1 - Off-label
|
HER-2 overexpression
HER-2 overexpression
|
Endometrial Cancer
Endometrial Cancer
|
trastuzumab
Sensitive: C1 - Off-label
|
HER-2 overexpression
HER-2 overexpression
|
Esophageal Cancer
Esophageal Cancer
|
trastuzumab
Sensitive: C1 - Off-label
|
HER-2 overexpression
HER-2 overexpression
|
Pancreatic Cancer
Pancreatic Cancer
|
trastuzumab
Sensitive: C1 - Off-label
|
HER-2 overexpression
HER-2 overexpression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab
Sensitive: C1 - Off-label
|
HER-2 overexpression
HER-2 overexpression
|
Cervical Cancer
Cervical Cancer
|
trastuzumab
Resistant: C1 - Off-label
|
HER-2 overexpression
HER-2 overexpression
|
Urothelial Cancer
Urothelial Cancer
|
trastuzumab
Sensitive: C1 - Off-label
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
ASLAN001
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
HER-2 overexpression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
HER-2 overexpression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
RC48
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
HER-2 overexpression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
HM 78136B
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
HER-2 overexpression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
pembrolizumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
HER-2 overexpression
|
Non Small Cell Lung Cancer
NSCLC
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Her-VAXX
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
HER-2 overexpression
|
Urothelial Cancer
Urothelial Cancer
|
RC48
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
HER-2 overexpression
|
Biliary Tract Cancer
Biliary Tract Cancer
|
ZW25
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
|
cetuximab
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
|
KN046 + KN026
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
RC48
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
cabazitaxel
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Esophageal Adenocarcinoma
Esophageal Adenocarcinoma
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Endometrial Cancer
Endometrial Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Ovarian Cancer
Ovarian Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Non Small Cell Lung Cancer
NSCLC
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Pancreatic Cancer
Pancreatic Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Bladder Cancer
Bladder Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
ZW25
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
ZW25
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
AT101
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
|
EGFR inhibitor
Resistant: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
simvastatin
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Uterine Cancer
Uterine Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
|
ado-trastuzumab emtansine
Sensitive: C4 – Case Studies
|
HER-2 overexpression
HER-2 overexpression
|
|
T-lymphocyte cell therapy
Sensitive: D – Preclinical
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
olaparib + niraparib + SYD985
Sensitive: D – Preclinical
|
HER-2 overexpression
HER-2 overexpression
|
Ovarian Cancer
Ovarian Cancer
|
brusatol
Sensitive: D – Preclinical
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
brusatol
Sensitive: D – Preclinical
|
HER-2 overexpression
HER-2 overexpression
|
Endometrial Cancer
Endometrial Cancer
|
DHES0815A
Sensitive: D – Preclinical
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
ado-trastuzumab emtansine + pertuzumab
Sensitive: D – Preclinical
|
HER-2 overexpression
HER-2 overexpression
|
Breast Cancer
Breast Cancer
|
ribociclib
Sensitive: D – Preclinical
|
